Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.
Press releases published on May 8, 2025
Exagen Inc. Prices Public Offering of Common Stock
GlobeNewswire
·
May 8, 2025
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock …
Nerve Calm Complaints Investigated: 2025 User Reviews Tested & Verified
GlobeNewswire
·
May 8, 2025
Discover Nerve Calm – the no 1 supplement designed to soothe nerves, reduce stress, and promote overall well-being. With natural ingredients like L-Theanine, Ashwagandha, and Magnesium, Nerve Calm helps enhance mood, support better sleep, and boost mental …
Arialief Complaints Exposed: 2025 User Reviews Analyzed and Verified
GlobeNewswire
·
May 8, 2025
FINDLAY, Ohio, May 08, 2025 (GLOBE NEWSWIRE) -- What is Arialief? Arialief is a premium natural dietary supplement formulated to support joint health, reduce chronic inflammation, and improve mobility in people suffering from musculoskeletal discomfort. It …
STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference
GlobeNewswire
·
May 8, 2025
HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic …
Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025
GlobeNewswire
·
May 8, 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to treating the core symptoms of autism spectrum disorder (ASD), today announced positive Phase 2 results for L1-79, presented at the …
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations
GlobeNewswire
·
May 8, 2025
New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disclosed AlpineBrook convertible notes. SANTA ANA, Calif., …
IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
GlobeNewswire
·
May 8, 2025
Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian …
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 2024 1Q 2025 net income of $13M, + 24% v. 1Q 2024 1Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024 Advanced pipeline: Expect to submit sBLA for …
Beyond Green Welcomes Six New Member Properties
GlobeNewswire
·
May 8, 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Beyond Green, a global portfolio of some of planet Earth’s most sustainable accommodations, is pleased to announce the addition of six new member properties to its global portfolio between January 1 and March 31, …
Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 8, 2025
-- Revenues increase 22% year over year driven by 90% growth in Zola® -- -- Arcadia sells patents for $750K and eliminates $1M in liabilities -- -- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 ( …
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
GlobeNewswire
·
May 8, 2025
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting
GlobeNewswire
·
May 8, 2025
PRINCETON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and infectious …
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of …
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
GlobeNewswire
·
May 8, 2025
Approximately 15 million USD Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases Oryzon will explore Aggression in specific subsets of Autism Spectrum Disorder (ASD) to expand the precision …
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development
GlobeNewswire
·
May 8, 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer and Board Member. Huerga brings over …
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
GlobeNewswire
·
May 8, 2025
– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively -- -- …
Stryker declares an $0.84 per share quarterly dividend
GlobeNewswire
·
May 8, 2025
Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, …
Merus to Present at BofA Securities 2025 Health Care Conference
GlobeNewswire
·
May 8, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D …
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
·
May 8, 2025
Norwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on- …
Cassava Reports Q1 2025 Financials Results, Provides Business Update
GlobeNewswire
·
May 8, 2025
License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences …